Simulations Plus : to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference
January 28, 2016 at 01:32 am IST
Share
Simulations Plus to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference
Business Wire via CMTX - Tue Jan 26, 7:30AM CST
Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, announced today that Walt Woltosz, Chairman and Chief Executive Officer, will provide a company overview at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference on Thursday, February 11, 2016, at 8:30 a.m. EST. The conference will be held at the Convene Conference Center at 730 Third Avenue in New York City. Simulations Plus management will be available during the day for one-on-one meetings.
For more information on the conference or to register, please go to www.SourceCapitalConference.com. A copy of the investor presentation that will accompany management's group presentation will be available at the Simulations Plus corporate website - www.simulations-plus.com.
About Simulations Plus, Inc.Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical and biotechnology agents. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into our software have made us the leading software provider for physiologically based pharmacokinetic modeling and simulation as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions. For more information, visit our website at www.simulations-plus.com.
About Source Capital GroupSource Capital Group, Inc. was founded in 1992 on the belief that the best investment advice should be independent, unbiased and tailor-made for the individual client's needs. Source Capital began as a boutique investment banking firm specializing in small to medium sized transactions. We have grown to include businesses in general securities, emerging market securities, distressed and high yield debt securities, in addition to our investment banking activity. http://www.sourcegrp.com/.
Simulations Plus Inc. issued this content on 26 January 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 27 January 2016 20:01:25 UTC
Original Document: http://www.simulations-plus.com/PressReleaseDetails.aspx?pID=450
Simulations Plus, Inc. is a provider of modeling and simulation software and services for pharmaceutical drug discovery and development, including the prediction of properties of molecules utilizing both artificial intelligence and machine-based technology. Its segments include software and services. It offers 12 software products for pharmaceutical research and development: GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, MonolixSuite, ADMET Predictor and MedChem Designer. Its services include population pharmacokinetic and pharmacodynamic, quantitative systems pharmacology/quantitative systems toxicology, and physiologically based pharmacokinetic. The Company provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions supporting product approval. The Company also provides tech-enabled training and compliance solutions for clinical trial investigators and site staff.
SIMULATIONS PLUS, INC. 
